Pharmaceutical MNCs Chalked Up Impressive Growth In China
This article was originally published in PharmAsia News
Executive Summary
Even as the pharmaceutical industry worldwide experiences a slowdown, most MNCs in China chalked up an average growth of over 20 percent in 2007, higher than the previous year's 15 percent. GSK China (including Hong Kong) turned in a 24 percent increase, with prescription drugs jumping to 30 percent, in contrast to its global 2 percent growth. AstraZeneca's sales grew 25 percent in China and Hong Kong while Roche enjoyed a 30 percent hike. Novartis's sales increased by 24.8 percent, with generics revenue surging 27 percent. Little surprise then that pharmaceutical MNCs are stepping up their investment in China and other emerging markets to compensate for their losses in developed countries. (Click here for more - Chinese Language)
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.